China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone86-10-6598-3111
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$466.88 million
Profitability
Miscellaneous
Employees2,187
Next Earnings Date5/3/2019 (Estimated)
OptionableOptionable
China Biologic Products (NASDAQ:CBPO) Frequently Asked Questions
What is China Biologic Products' stock symbol?
China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO."
How were China Biologic Products' earnings last quarter?
China Biologic Products Holdings Inc (NASDAQ:CBPO) issued its earnings results on Wednesday, March, 6th. The biopharmaceutical company reported $0.76 earnings per share for the quarter, missing analysts' consensus estimates of $0.83 by $0.07. The biopharmaceutical company had revenue of $114.90 million for the quarter, compared to the consensus estimate of $116.35 million. China Biologic Products had a return on equity of 9.54% and a net margin of 27.43%. China Biologic Products's revenue for the quarter was up 27.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.32 EPS. View China Biologic Products' Earnings History.
When is China Biologic Products' next earnings date?
What price target have analysts set for CBPO?
3 equities research analysts have issued 12-month target prices for China Biologic Products' shares. Their predictions range from $62.00 to $88.00. On average, they expect China Biologic Products' stock price to reach $78.00 in the next year. This suggests that the stock has a possible downside of 20.6%. View Analyst Price Targets for China Biologic Products.
What is the consensus analysts' recommendation for China Biologic Products?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for China Biologic Products in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for China Biologic Products.
Has China Biologic Products been receiving favorable news coverage?
News coverage about CBPO stock has been trending positive recently, according to InfoTrie. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. China Biologic Products earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Who are some of China Biologic Products' key competitors?
Some companies that are related to China Biologic Products include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN) and Crispr Therapeutics (CRSP).
What other stocks do shareholders of China Biologic Products own?
Who are China Biologic Products' key executives?
China Biologic Products' management team includes the folowing people:
- Mr. Ming Yang, Chief Financial Officer (Age 47)
- Mr. Ming Yin, Sr. VP (Age 41)
- Ms. Zhijing Liu, Corp. VP (Age 65)
- Mr. Gang Yang, Corp. VP & GM of Guizhou Taibang (Age 54)
- Dr. Bing Li Ph.D., CEO & Director (Age 51)
How do I buy shares of China Biologic Products?
Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is China Biologic Products' stock price today?
One share of CBPO stock can currently be purchased for approximately $98.19.
How big of a company is China Biologic Products?
China Biologic Products has a market capitalization of $3.86 billion and generates $466.88 million in revenue each year. The biopharmaceutical company earns $128.06 million in net income (profit) each year or $4.02 on an earnings per share basis. China Biologic Products employs 2,187 workers across the globe.
What is China Biologic Products' official website?
How can I contact China Biologic Products?
China Biologic Products' mailing address is 18TH FL JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD CHAOYANG DISTRICT, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected]
MarketBeat Community Rating for China Biologic Products (NASDAQ CBPO)
MarketBeat's community ratings are surveys of what our community members think about China Biologic Products and other stocks. Vote "Outperform" if you believe CBPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
